Outlook Therapeutics, Inc.
OTLKHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. With a market capitalization of $161.7M, it sits in micro-cap territory. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Market Cap
$161.7M
Beta
0.75
P/E (TTM)
—
P/E (Fwd)
-4.76
EPS (TTM)
$-0.72
EPS (Fwd)
$-0.14
ROE
—
ROA
-143.2%
Cash
$11.2M
Total Debt
$18.4M
Free CF
-$37.4M
52W Change
-31.4%
Annual Financials
Cash vs Debt
Where OTLK stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, OTLK finished 8.70% below its 150-day moving average ($0.69) and 27.59% below its 200-day moving average ($0.87). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OTLK overbought or oversold?
At the September 3, 2026 close, OTLK's RSI(14) was 19.5, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $11.2M in cash, though total debt stands at $18.4M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$37.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Outlook Therapeutics, Inc. and its sector.